多靶点抗原肽自体免疫细胞技术联合甲磺酸阿帕替尼辅助化疗治疗转移性软组织肉瘤的临床分析

Clinical analysis of MASCTTM as adjuvant chemotherapy in the treatment of metastatic soft tissue sarcoma

目的探讨多靶点抗原肽自体免疫细胞技术联合甲磺酸阿帕替尼(MASCTTM)辅助化疗治疗转移性软组织肉瘤(STS)的临床疗效。方法依据治疗方法的不同将61例转移性STS患者分为观察组(n=31)和对照组(n=30),观察组患者接受MASCTTM辅助化疗,对照组患者单纯接受化疗。比较两组患者的近期疗效、生存情况及不良反应发生情况。结果观察组患者的疾病控制率(DCR)为83.9%(26/31),高于对照组的60.0%(18/30),差异有统计学意义(P﹤0.05)。观察组患者的1年累积生存率为83.9%,高于对照组的56.7%(P﹤0.05);观察组患者的2年累积生存率为51.5%,高于对照组的26.7%(P﹤0.05)。两组患者骨髓抑制、消化道反应、心脏毒性的发生情况比较,差异均无统计学意义(P﹥0.05)。结论MASCTTM辅助化疗治疗转移性STS的近远期疗效显著,且安全性高,具有临床推广价值。

Objective To investigate the clinical effect of multiple antigen stimulating cellular therapy combined with apatinib mesylate(MASCTTM)as adjuvant chemotherapy in the treatment of metastatic soft tissue sarcoma(STS).Method A retrospective analysis including 61 patients with metastatic STS was performed,these patients were divided into two groups as study group(n=31)or control group(n=30),those who in study group were treated with MASCTTM as adjuvant chemotherapy,and the control group was treated with chemotherapy alone.The short-term efficacy,survival and incidence of adverse reactions were evaluated and compared between the two groups.Result The disease control rate(DCR)in study group was 83.9%(26/31),which was higher than the 60.0%(18/30)in control group,indicating statistically significant difference(P<0.05).The 1-year cumulative survival rate was 83.9%in study group versus 56.7%in control group,there was also statistically significant inter-group difference(P<0.05);for 2-year cumulative survival rate in study group and control group,the results of 51.5%and 26.7%were observed,respectively(P<0.05).There was no significant difference in respect to the incidence of myelosuppression,digestive tract reaction and cardiac toxicities between the two groups(P>0.05).Conclusion The short-term and long-term efficacy of MASCTTM as adjuvant chemotherapy in the treatment of metastatic soft tissue sarcomas are significant,with high safety and great clinical value.